Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.

scientific article published in July 1997

Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID9253507

P2093author name stringMartuza RL
Miyatake S
Rabkin SD
P433issue4
P921main subjectvector-borne diseaseQ2083837
P304page(s)222-228
P577publication date1997-07-01
P1433published inCancer Gene TherapyQ15763088
P1476titleDefective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma
P478volume4

Reverse relations

cites work (P2860)
Q36325239Current immunotherapeutic strategies for central nervous system tumors
Q37103315Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment
Q42360056Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression
Q33995752HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications
Q28476019Inhibition of glioblastoma growth by the thiadiazolidinone compound TDZD-8
Q33618760Progression of motor deficits in glioma-bearing mice: impact of CNF1 therapy at symptomatic stages
Q34786262Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.
Q92966660Rodent Glioma Models: Intracranial Stereotactic Allografts and Xenografts
Q37269915Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.
Q35189981The bacterial protein toxin, cytotoxic necrotizing factor 1 (CNF1) provides long-term survival in a murine glioma model

Search more.